CLDN8 and triple-negative breast carcinoma: CLDN8 expression was also assessed in different molecular subtypes of breast cancer, including ER(+), HER2(+), ER(+)/HER2(+), and triple-negative breast cancer (TNBC) subtypes (Figure 2C).